News

The FDA’s decision to approve the indication expansion was based on a placebo-controlled clinical phase III study (Study 332) of Fycompa in 164 patients aged 12 years and

ImMucin is an immunotherapeutic treatment which educates the MM patient’s immune system, particularly T-cells and antibodies, to attack MM cancer cells via a specific domain, termed signal peptide,

Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence (RWE)

As previously reported, oral treatment with Optina (low-dose danazol) has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal

The application covers InVivo’s investigational Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial and has been successfully implanted in three patients. Also covered is

The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD + UL46) vaccine, each formulated with Vical’s

The new TCR candidates are directed against the HPV type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies to efficiently modify certain genes to improve T cell

The new intravenous antiplatelet agent adds to the company’s commercial offerings in the cardiac cath lab. The company intends to introduce kengreal, which is the first and only

L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based upon its new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental